FOR RETINAL NEURODEGENERATIVE DISAESE: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the independent Data Safety Monitoring Board (DSMB) completed its second planned safety review of the […]